Selah Genomics

Selah Genomics is a biotechnology company focused on advanced genomic testing solutions that enhance personalized medicine through genomic sequencing and analysis tools for clinical and research applications. Selah Genomics specializes in genomic testing services, providing insights that empower healthcare decisions. The company is headquartered in Greenville, US. In April 2014, Selah Genomics was acquired by EKF Diagnostics for USD 40.

00 mn, with an additional USD 35. 00 mn contingent on specific performance milestones. Selah Genomics specializes in advanced genomic testing solutions, providing a range of products and services aimed at enhancing personalized medicine. Their core offerings include genomic sequencing and analysis tools that cater to both clinical and research applications.

These services are designed to identify genetic variations that can influence health outcomes, enabling healthcare providers to make informed decisions tailored to individual patient needs. The company targets a diverse client base, including hospitals, research institutions, and biotechnology firms, primarily in North America and Europe. The end users of Selah Genomics’ products encompass healthcare practitioners and researchers seeking to leverage genomic data for more effective treatment strategies and innovative research initiatives. Selah Genomics generates revenue through a combination of direct sales and service agreements, with a focus on B2B transactions.

Clients typically engage with the company through tailored service packages that may include one-time genomic analyses or ongoing subscription-based access to their genomic testing platforms. The pricing structure reflects the complexity and scope of services chosen, with flagship products designed to meet specific clinical needs and research standards. Revenue is derived not only from the sale of individual tests but also from partnerships with healthcare providers and research organizations that integrate Selah Genomics’ offerings into their operational frameworks. This multifaceted approach to revenue generation positions the company to effectively serve the growing demand for genomic insights across various healthcare and research sectors.

Selah Genomics plans to leverage recent funding to enhance its product offerings and expand into new markets. The company is currently designing new genomic testing products, which are expected to launch in the coming years. Furthermore, Selah Genomics aims to penetrate additional markets in Asia and South America by 2025, aiming to broaden its impact globally. The acquisition by EKF Diagnostics not only provided USD 40.

00 mn for immediate growth initiatives but also allows for an additional USD 35. 00 mn contingent upon achieving specific milestones, which will support these strategic expansions.